Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26213169 | 0.87 | CYP3A4 (0.43) | KDM1AHDAC6CARM1PRMT6 | |
| SCHEMBL26213063 | 0.87 | EPHX2 (0.51) | KDM1AHDAC6EPHX2 | |
| SCHEMBL26213116 | 0.86 | KDM1A (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213111 | 0.86 | L3MBTL1 (0.42) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL30270456 | 0.80 | CARM1 (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213112 | 0.80 | CARM1 (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213120 | 0.79 | PRMT6 (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL30270433 | 0.79 | PRMT6 (0.43) | KDM1AHDAC6CARM1PRMT6SLC6A2 | |
| SCHEMBL26213106 | 0.76 | SIGMAR1 (0.43) | KDM1AHDAC6EPHX2 | |
| SCHEMBL26213069 | 0.75 | SIGMAR1 (0.44) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | KDM1A 859/4885HDAC6 203/4885CARM1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.